Recent Research Analysts’ Ratings Updates for Surmodics (SRDX)

A number of research firms have changed their ratings and price targets for Surmodics (NASDAQ: SRDX):

  • 6/8/2024 – Surmodics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 5/30/2024 – Surmodics had its “market perform” rating reaffirmed by analysts at Barrington Research.
  • 5/30/2024 – Surmodics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
  • 5/29/2024 – Surmodics had its “neutral” rating reaffirmed by analysts at Sidoti. They now have a $43.00 price target on the stock.
  • 5/29/2024 – Surmodics had its “hold” rating reaffirmed by analysts at Lake Street Capital. They now have a $43.00 price target on the stock.
  • 5/29/2024 – Surmodics had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
  • 5/2/2024 – Surmodics had its “outperform” rating reaffirmed by analysts at Barrington Research. They now have a $71.00 price target on the stock.
  • 5/1/2024 – Surmodics had its price target lowered by analysts at Needham & Company LLC from $47.00 to $43.00. They now have a “buy” rating on the stock.
  • 4/24/2024 – Surmodics was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
  • 4/16/2024 – Surmodics was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.

Surmodics Price Performance

NASDAQ:SRDX opened at $41.86 on Tuesday. Surmodics, Inc. has a one year low of $22.15 and a one year high of $42.36. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.59 and a current ratio of 4.39. The stock has a market cap of $596.92 million, a PE ratio of 44.06 and a beta of 1.17. The stock has a 50 day moving average price of $31.93 and a 200 day moving average price of $32.57.

Surmodics (NASDAQ:SRDXGet Free Report) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $0.07 EPS for the quarter, beating the consensus estimate of ($0.36) by $0.43. Surmodics had a return on equity of 13.30% and a net margin of 9.44%. The firm had revenue of $31.96 million during the quarter, compared to analysts’ expectations of $28.79 million. During the same quarter last year, the firm earned ($0.40) earnings per share. Equities research analysts expect that Surmodics, Inc. will post -0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Surmodics

Several hedge funds and other institutional investors have recently made changes to their positions in SRDX. Lazard Asset Management LLC increased its stake in Surmodics by 13.4% during the first quarter. Lazard Asset Management LLC now owns 5,679 shares of the company’s stock worth $166,000 after acquiring an additional 673 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Surmodics during the first quarter worth $1,270,000. Acadian Asset Management LLC increased its stake in Surmodics by 11.3% during the first quarter. Acadian Asset Management LLC now owns 408,779 shares of the company’s stock worth $11,988,000 after acquiring an additional 41,617 shares during the last quarter. Vanguard Group Inc. increased its stake in Surmodics by 0.7% during the first quarter. Vanguard Group Inc. now owns 865,214 shares of the company’s stock worth $25,385,000 after acquiring an additional 5,927 shares during the last quarter. Finally, SG Americas Securities LLC increased its stake in Surmodics by 14.7% during the first quarter. SG Americas Securities LLC now owns 5,138 shares of the company’s stock worth $151,000 after acquiring an additional 660 shares during the last quarter. Institutional investors and hedge funds own 96.63% of the company’s stock.

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).

See Also

Receive News & Ratings for Surmodics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc and related companies with MarketBeat.com's FREE daily email newsletter.